Midwives Revision

Oncology

Burkitt's Lymphoma

A highly aggressive B-cell Non-Hodgkin lymphoma, common in children in Uganda (endemic form), often associated with Epstein-Barr virus (EBV) and malaria co-infection. Typically presents with rapidly growing tumours, most commonly in the jaw or abdomen.

Also known as: BL

View images for Burkitt's Lymphoma (Google Images, opens in a new tab)
On this page

Referral and warning signs

When to refer

Immediate urgent referral to specialized cancer centre for ALL suspected cases.

Red flags

  • Rapidly growing jaw or abdominal mass in a child
  • Signs of bowel obstruction
  • Neurological deficits
  • Signs of tumour lysis syndrome (renal failure, electrolyte disturbance)

Signs and symptoms

  • Rapidly growing tumour/mass, often painless initially.
  • Jaw swelling (most common presentation in endemic form).
  • Abdominal mass / Abdominal distension / Pain.
  • Intestinal obstruction / Intussusception.
  • Ascites.
  • Bone marrow involvement: Anaemia, thrombocytopenia (bleeding), neutropenia (infections).
  • Central Nervous System (CNS) involvement: Headache, cranial nerve palsies, seizures, altered mental status.
  • Lymphadenopathy (less common than other lymphomas).
  • Constitutional symptoms (fever, night sweats, weight loss) may occur.

Risk factors

  • Childhood (peak age 4-7 years for endemic form).
  • Geographic location (endemic in malaria holoendemic areas of Africa).
  • Epstein-Barr Virus (EBV) infection.
  • Chronic malaria infection (immunosuppression/B-cell stimulation).
  • HIV infection (associated with sporadic/immunodeficiency-related BL).

Diagnosis

Clinical assessment

Suspect in a child from endemic area with rapidly growing jaw or abdominal mass.

Investigations

  • Biopsy of tumour mass (FNA or excisional/incisional): Essential for diagnosis. Histology shows characteristic 'starry sky' appearance. Immunohistochemistry confirms B-cell origin.
  • Bone Marrow Aspiration and Biopsy: Assess for marrow involvement.
  • Lumbar Puncture with CSF analysis (cytology): Assess for CNS involvement.
  • Blood tests: CBC (cytopenias), LDH (Lactate Dehydrogenase - often very high, marker of tumour burden/turnover), Uric Acid (risk of tumour lysis syndrome), Renal/Liver function tests.
  • Imaging: Abdominal Ultrasound/CT scan (assess abdominal disease extent), Chest X-ray.
  • HIV testing.

Diagnostic criteria

Histopathological confirmation from biopsy.

Management

Non-pharmacological management

  • Urgent referral to specialized cancer centre (UCI/RRH).
  • Supportive care: Management of tumour lysis syndrome (hydration, allopurinol/rasburicase), infection control, nutritional support.

Pharmacological treatment

  • Intensive multi-agent chemotherapy is the mainstay of treatment. Highly sensitive to chemo, cure rates high if treated appropriately.
  • Specific protocols depend on stage and risk group (specialist management). Often include drugs like Cyclophosphamide, Vincristine, Methotrexate, Cytarabine, Doxorubicin, Rituximab.
  • CNS prophylaxis/treatment is essential.

Monitoring

Close monitoring for treatment response and toxicity (myelosuppression, tumour lysis syndrome, infections). Long-term follow-up for relapse.

Complications

  • Tumour Lysis Syndrome (metabolic emergency with chemo initiation)
  • Bowel obstruction/perforation
  • CNS involvement
  • Spinal cord compression
  • Treatment-related toxicity (myelosuppression, infertility, secondary malignancies)

Prevention

  • Malaria control may play a role in reducing endemic BL incidence.

Patient education

  • (To parents/guardians) Explain Burkitt's lymphoma as a fast-growing but treatable cancer.
  • Need for urgent referral and intensive chemotherapy.
  • Explain treatment plan, potential side effects, need for supportive care.
  • Importance of adherence and follow-up.

Uganda-specific notes

Endemic Burkitt's lymphoma is the most common childhood cancer in Uganda. Strongly linked to EBV and malaria. UCI has established treatment protocols.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 12, Section 12.3.1

  • Uganda Cancer Institute Treatment Guidelines

    (Specific protocols)

For learning and professional reference. Use current local guidance and clinical judgement.

Browse all conditions

Want notes in PDF? Join our classes!!

Send us a message on WhatsApp
0726113908

Scroll to Top